Action of cilostazol in diabetic and non-diabetic rats as prevention of atherosclerosis




Cilostazol; Atherosclerosis; Diabetes mellitus.


Atherosclerosis is a chronic inflammatory disease of multifactorial origin that occurs in response to endothelial aggression, affecting mainly the intimal layer of medium and large arteries. Type 2 diabetes mellitus is associated with a high rate of atherosclerotic cardiovascular disease. This study aims to analyze the impact, by drug treatment of Cilostazol, which is an antiplatelet drug, on the reduction of the aortic artery thickness of rats induced to develop diabetes through the administration of streptozotocin, compared to a control group without diabetes. The study showed that the time it took for the rat to develop diabetes was 8 weeks, the rats in the group that was administered streptozotocin showed a significant increase in aortic arterial thickness, especially in the intimal layer of the artery. A reduction in the thickness of the intimal layer of the aorta arteries of the rats submitted to treatment with cilostazol was observed, with significant significance when comparing the groups with diabetes and even when comparing the rats that were not induced to diabetes, showing that cilostazol can be a great ally in preventing atherosclerosis.


Amarante, R., Castro, R., Lage, A., & Cisternas, J. (2007). Diabetes Mellitus como fator de risco na aterogênese. Arq Med Hosp Fac Cienc Med Santa Casa São Paulo, 52(3), 87–93.

Andreollo, N. A., Santos, E. F. dos, Araújo, M. R., & Lopes, L. R. (2012). Idade dos ratos versus idade humana: qual é a relação? ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 25(1), 49–51.

Bahia, L., Guilherme, L., Aguiar, K., Villela, N. R., Bottino, D., & Bouskela, E. (2004). Endotélio e aterosclerose. Revista Da SOCERJ, 17, 26–32.

Bangalore, S., Singh, A., Toklu, B., DiNicolantonio, J. J., Croce, K., Feit, F., & Bhatt, D. L. (2014). Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: Insights from a meta-analysis of randomised trials. Open Heart, 1(1), 1–18.

Chapman, T. M., & Goa, K. L. (2003). Cilostazol. American Journal of Cardiovascular Drugs, 3(2), 117–138.

Cilostazol. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (n.d.). PubMed. (2017). 450(Md), 1–5.

Delfino, V. D., Figueiredo, J. F., Matsuo, T., Favero, M. E., Matni, A. M., & Mocelin, A. (2002). Diabetes mellitus induzido por estreptozotocina: comparaçäo em longo prazo entre duas vias de administraçäo. J. Bras. Nefrol., 24(1), 31–36.

Furman, B. L. (2015). Streptozotocin-Induced Diabetic Models in Mice and Rats. Current Protocols in Pharmacology, 70, 5.47.1-5.47.20.

Hong, S., Nam, M., Little, B., Paik, S., Lee, K., Woo, J., & vessels, D. K.-H., 2019, undefined. (n.d.). Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. Springer.

Hotta, V. T., Rangel, D. D. do N., Tavares, G. M. P., Mangini, S., & Lemos, P. A. (2017). Diagnosis and treatment of rare complication after endomyocardial biopsy. Arquivos Brasileiros de Cardiologia, 109(6), 618–619.

Induce, F. T., & Atherogenesis, I. O. R. (2008). Inflammation or Atherogenesis. Health (San Francisco), 115–126.

Jung, K. I., Kim, J. H., Park, H. Y. L., & Park, C. K. (2013). Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. Journal of Pharmacology and Experimental Therapeutics, 345(3), 457–463.

Junod, A., Lambert, A. E., Orci, L., Pictet, R., Gonet, A. E., & Renold, A. E. (1967). Studies of the Diabetogenic Action of Streptozotocin. Proceedings of the Society for Experimental Biology and Medicine, 126(1), 201–205.

Junod, A., Lambert, A. E., Stauffacher, W., & Renold, A. E. (1969). Diabetogenic action of streptozotocin: relationship of dose to metabolic response. The Journal of Clinical Investigation, 48(11), 2129–2139.

Kolb, H. (1987). Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes/Metabolism Reviews, 3(3), 751–778.

Lee, D. H., Chun, E. J., Oh, T. J., Kim, K. M., Moon, J. H., Choi, S. H., Park, K. S., Jang, H. C., & Lim, S. (2019). Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes, Obesity and Metabolism, 21(6), 1409–1418.

Lee, J. H., Oh, G. T., Park, S. Y., Choi, J. H., Park, J. G., Kim, C. D., Lee, W. S., Rhim, B. Y., Shin, Y. W., & Hong, K. W. (2005). Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. Journal of Pharmacology and Experimental Therapeutics, 313(2), 502–509.

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 1–18.

Omi, H., Okayama, N., Shimizu, M., Fukutomi, T., Nakamura, A., Imaeda, K., Okouchi, M., & Itoh, M. (2004). Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvascular Research, 68(2), 119–125.

Park, J.-S., & Kim, Y.-J. (2008). The Clinical Effects of Cilostazol on Atherosclerotic Vascular Disease. REVIEW Korean Circ J, 38, 441–445.

Rakieten, N., Rakieten, M. L., & Nadkarni, M. V. (1963). Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemotherapy Reports, Rep. 1963 May; 29, 91–98.

Rogers, K. C., Oliphant, C. S., & Finks, S. W. (2015). Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature. Drugs, 75(4), 377–395.

Sallustio, F., Rotondo, F., Di Legge, S., & Stanzione, P. (2010). Cilostazol in the Management of Atherosclerosis. Current Vascular Pharmacology, 8(3), 363–372.

Santos, M. G. dos, Pegoraro, M., Sandrini, F., & Macuco, E. C. (2008). Desenvolvimento da aterosclerose na infância-Artigo de Revisão. Arquivos Brasileiros de Cardiologia, 90(4), 301–308.

Wan, H., Huang, T., Yang, P., Wu, T., Zhang, H., & Wu, Q. (2022). Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 79(3), 390–398.

Weintraub, W. S. (2006). The vascular effects of cilostazol. Canadian Journal of Cardiology, 22(SUPPL. B), 56B-60B.

Wilhite, D. B., Comerota, A. J., Schmieder, F. A., Throm, R. C., Gaughan, J. P., & Rao, A. K. (2003). Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. Journal of Vascular Surgery, 38(4), 710–713.

Xie, T. Y., Yan, W., Lou, J., & Chen, X. Y. (2016). Effect of ozone on vascular endothelial growth factor (VEGF) and related inflammatory cytokines in rats with diabetic retinopathy. Genetics and Molecular Research, 15(2), 1–11.

Yoshikawa, T., Mitani, K., Kotosai, K., Nozako, M., Miyakoda, G., & Yabuuchi, Y. (2008). Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Hormone and Metabolic Research, 40(7), 473–478.



How to Cite

SILVA, D. F.; REIS, E. S. dos S. .; KOGA, A. Y. .; SCHEBELSKI, D. J. .; COSTA, M. A. C. da . Action of cilostazol in diabetic and non-diabetic rats as prevention of atherosclerosis . Research, Society and Development, [S. l.], v. 12, n. 4, p. e12812440968, 2023. DOI: 10.33448/rsd-v12i4.40968. Disponível em: Acesso em: 27 feb. 2024.



Health Sciences